AviClear becomes the fastest adopted device in Cutera’s history BRISBANE, Calif.–(BUSINESS WIRE)–Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announces that over 1,000 AviClear laser treatments have been performed in the United States. AviClear is the first and only energy-based device to be FDA-cleared for the … [Read more…]
PHILADELPHIA & WESTERVILLE, Ohio–(BUSINESS WIRE)–#LLR—LLR Partners today announced a significant growth investment in Vantage Point Logistics (“VPL”), a supply chain management software provider that helps healthcare organizations improve resiliency and visibility of clinical supply chains. The capital will be used to support VPL’s continued product innovation and organic growth along with the exploration of strategic … [Read more…]
Silver has decades of experience in shepherding products, including molecular diagnostics, to commercialization within the medical and consumer industries BETHESDA, Md. & GAITHERSBURG, Md.–(BUSINESS WIRE)–Longhorn Vaccines and Diagnostics LLC, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, announced today that Zoe Silver has joined the company as … [Read more…]
OXFORD, England–(BUSINESS WIRE)–Exscientia plc (Nasdaq: EXAI) today announced that Caroline Rowland has joined Exscientia as Chief People Officer. In this newly created role, she will lead Exscientia’s People (human resources) and Places functions and build on the Company’s talent, training and employee experience strategies. Caroline reports to CEO and Founder, Andrew Hopkins, DPhil. “Exscientia was … [Read more…]
LAUSANNE, Switzerland & TEL AVIV, Israel–(BUSINESS WIRE)–#biomarker—Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Nucleai, a leader in AI-powered spatial biology transforming precision medicine by unlocking the power of pathology data, today announced a collaboration to accelerate the discovery of novel biomarkers and drug targets using the … [Read more…]
ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced the application for certification of the ALLY™ Adaptive Cataract Treatment System (“ALLY” or the “ALLY System”) in the European Union. “Following the FDA clearance of ALLY … [Read more…]
– New state-of-the art manufacturing facility is designed to enable the reliable production of Orca Bio’s investigational cell therapies from late-stage clinical development through potential commercialization – – The 100,000-square-foot facility is located in Metro Air Park, Sacramento – MENLO PARK, Calif.–(BUSINESS WIRE)–Orca Bio, a late-stage biotechnology company developing high-precision cell therapies for the treatment … [Read more…]
– Phosphorylation-inducing chimeric small molecules (PHICS) are a new class of bifunctional medicines that direct and repair aberrant and dysfunctional proteins – PHICS enable precise phosphorylation, an important post-translational modification that controls protein function, including activation, stabilization, trafficking, inactivation, and degradation – Led by a strong foundational management team of respected industry veterans with deep … [Read more…]
IRVINE, Calif.–(BUSINESS WIRE)–Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the first patient implants in Canada with the Axonics F15™, the company’s newly developed, long-lived, fully recharge-free sacral neuromodulation (SNM) system. The University of Alberta implanted four … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Antifungal Drugs Market By Drug Class, By Infection Type, By Therapeutic Indications, By Dosage Forms: Global Opportunity Analysis and Industry Forecast, 2020-2030” report has been added to ResearchAndMarkets.com’s offering. The anti-fungal drugs market was valued at $16,572.1 million in 2020, and is estimated to reach $25,045.20 million by 2030, growing at a CAGR … [Read more…]
